A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form
Clinical trial NCT06540352 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06540352
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-03
- Primary completion
- 2026-12-31
- Enrollment
- 175
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.